Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Funding for this research was provided by:
National Key R&D Program of China (2016YFC0905500, 2016YFC0905503)